Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

ClinTec Starts Operations in Malawi

Published: Thursday, August 16, 2012
Last Updated: Thursday, August 16, 2012
Bookmark and Share
Leading pharmaceutical company selects ClinTec as partner of choice in Africa and Asia.

ClinTec International has expanded its operations into Malawi, appointing its first highly experienced clinical research associates.

A top 5 pharmaceutical company with sales exceeding US$50 billion has selected ClinTec as its preferred partner for vaccine development in Africa and Asia, further enhancing ClinTec’s growing presence in the emerging markets of Africa, Asia and the Middle East. The global vaccines market has an estimated value of US$33.8 billion.

Africa is a pivotal region for the development of adult and paediatric vaccines against infectious diseases and ClinTec is well placed to participate in these programmes.

The company is in the process of recruiting highly skilled personnel with vaccine research experience to join its already established teams in Africa and Asia, in preparation for strong growth ahead from these geographic markets.

Vaccine development faces its own challenges associated with local immunization recommendations as well as stringent cold chain management.

ClinTec’s team has the experience and understanding of the local challenges involved in working effectively in Africa and Asia, whilst complying in full with international clinical research guidelines.

ClinTec, winner of the 2011 Queen’s Award for Enterprise, operates in over 40 countries to provide specialist clinical research personnel and support services to its clients, which includes 11 of the top 25 pharmaceutical companies.

ClinTec has grown organically since its inception in the UK in 1997, and has recently reported a 429 percent growth rate over the 5-year period from 2006 to 2011.

It was one of the first CROs to establish a presence in the Middle East and Africa and has continued to strengthen its presence in the emerging markets as well as the more traditional Western European clinical research marketplace.

Commenting on the opening of ClinTec’s Malawi operations, Dr Rabinder Buttar stated: “I am pleased with our continued expansion in Africa and see huge potential for the company in conducting large scale vaccine trials. Despite the challenging economic conditions through which many of our clients are restructuring their organizations, ClinTec continues to grow and win major new business from pharma companies. The company is continuing to expand into interesting new regions for clinical research. As the pharmaceutical industry increasingly focuses its drug development efforts on the emerging markets, ClinTec will closely partner with its clients, aligning its services and operations to fit with their needs”.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
The Power Of Orthogonality In Assessing The Stability Of Biopharmaceuticals
By utilizing orthogonal techniques, researchers can maximize the secure application of all analytical results generated.
Dysfunction in Neuronal Transport Mechanism Linked to Alzheimer’s
Findings confirm mutation-caused problem but also reveal a new therapeutic target.
New Antibody Therapy Permanently Blocks SIV Infection
An international research team has developed an effective treatment strategy against the HIV-like Simian Immunodeficiency Virus (SIV) in rhesus macaques.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
DNA Vaccines Protect Monkeys Against Zika Virus
Two experimental Zika virus DNA vaccines developed by NIH scientists protected monkeys against Zika infection.
Rare Flu-Thwarting Mutation Discovered
Study finds protein mutation, that is encoded by influenza, causes the virus to lose any defence against the immune system.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos